

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: 6 month(s) and over

Healthy Volunteers: This study is NOT accepting healthy volunteers

Key Inclusion Criteria:

- Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive
- Age: Lower age limit of ≥ 6 months; adequate organ function
- Eastern Cooperative Oncology Group (ECOG)/Karnofsky Performance Status 0 or 1/70 and above at Screening.

Key Exclusion Criteria:

- Prior treatment with any anti-CD7 therapy.
- Patients with decompensated hemolytic anemia.
- Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.

Conditions & Interventions

Interventions:

BIOLOGICAL: WU-CART-007

Conditions:

T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Keywords:

CAR-T Therapy, Acute Leukemia

More Information

Description:

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

Contact(s): - cancer@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: PHASE2

IRB Number:

System ID: NCT06514794

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.